Advice for Mesothelioma Patients and Caregivers: Understanding Blood-Based Biomarkers

Advice for Mesothelioma Patients and Caregivers: Understanding Blood-Based Biomarkers

A pleural mesothelioma diagnosis can overwhelm patients and caregivers. However, knowing about recent research can help in making treatment decisions.

For example, a key area is blood-based biomarkers. Two promising ones are soluble mesothelin-related protein (SMRP) and cancer antigen 125 (CA-125). They help monitor pleural mesothelioma progression.

A new article published in Thoracic Cancer offers advice for mesothelioma patients and caregivers on these biomarkers.

Understanding SMRP and CA-125

SMRP and CA-125 are biomarkers found in the blood. They can provide valuable information about the presence and progression of pleural mesothelioma. SMRP levels tend to be elevated in patients with pleural mesothelioma, particularly those with epithelioid and biphasic histology.

On the other hand, CA-125 levels may indicate the presence of abdominal recurrences. These can be especially helpful in diagnosing the spread to the abdominal cavity.

Monitoring Biomarker Levels

If you or a loved one has pleurectomy decortication, it’s crucial to monitor SMRP and CA-125 levels. This should be done before and after surgery.

These tests can show disease progression and recurrence. Studies have linked changes in SMRP levels to local recurrence. Similarly, CA-125 levels may signal lymphatic or abdominal recurrence.

After surgery, it’s vital to track changes in SMRP and CA-125 levels. A drop in SMRP levels after surgery, followed by an increase later, might mean disease recurrence. Moreover, high CA-125 levels could indicate abdominal recurrence. Monitoring these levels over time is key. It helps in the early detection of recurrence and guides follow-up care.

Seeking Comprehensive Care

Blood-based biomarkers are useful for managing pleural mesothelioma. However, they’re just one tool in your care plan. Work closely with your healthcare team to tailor a treatment plan. This plan might include surgery, chemotherapy, and radiation. Regular check-ups and imaging are crucial for tracking your condition.

Stay informed about mesothelioma research and treatments. Talk to your doctor about joining clinical trials. These trials could provide new treatments or insights. Taking an active role in your care and staying informed helps you make the best health decisions.

Biomarkers like SMRP and CA-125 can track mesothelioma’s progress. Understanding their role helps patients and caregivers. It also improves post-surgery monitoring. Collaboration with your healthcare team and knowledge about research offer hope and optimism.

Source:

Paajanen, Juuso, Ahmed Sadek, William G. Richards, Yue Xie, Emanuele Mazzola, Kristina Sidopoulos, John Kuckelman, Ritu R. Gill, and Raphael Bueno. “Circulating SMRP and CA-125 before and after Pleurectomy Decortication for Pleural Mesothelioma.” Thoracic Cancer n/a, no. n/a. Accessed April 26, 2024. https://doi.org/10.1111/1759-7714.15264.

Similar Posts

  • | |

    Mesothelioma survivor Paul Kraus, alive and well 19 years after writing “Surviving Mesothelioma and Other Cancers

    Paul Kraus is considered the longest documented mesothelioma survivor in the world. He was diagnosed in 1997 with mesothelioma so widespread that he was given little hope of survival. Not willing to give up, he worked with a team of doctors to create his own tailored treatment protocol. This protocol included dramatic life style change, experimental therapies, dietary changes, mind-body medicine, and other modalities. Paul was fortunate. The protocol he and his doctors created helped him keep the mesothelioma in check. His book “Surviving Mesothelioma and Other Cancers: A Patient’s Guide” details his cancer voyage, the decisions he made, and his philosophies about health and healing. This book is now the best-selling mesothelioma book in the world and has inspired…

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…